| Jun 18, 2025 | PreciseDx | $11.0M Other Equity | Eventide Asset Management, Merck, Philips Ventures | Genhenn Capital, Labcorp, Quest Diagnostics |
| Aug 21, 2024 | PreciseDx | $20.7M Series B | Eventide Asset Management | Genhenn Capital, Labcorp, Quest Diagnostics |
| Feb 15, 2024 | Freenome | $254.0M Other Equity | Matt Sause | American Cancer Society, Andreessen Horowitz, ARK Invest, ArrowMark Partners, Bain Capital Life Sciences, Data Collective, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Mark A. Gardner, RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates |
| Sep 1, 2023 | Avalyn Pharma | $180.0M Series C | SR ONE, Eventide Asset Management, Gianna Hoffman Luca | B Capital Group, Northpond Ventures, Heather Preston, Catalio Capital, F Prime Capital, Norwest Venture Partners, Novo Holdings, Pivotal BioVenture Partners, RiverVest Venture Partners, Rock Springs Capital, Surveyor Capital, T. Rowe Price Associates, Vida Ventures, Wellington Management |
| Mar 1, 2023 | Flare Therapeutics | $120.0M Series B | Craig Gordon | 8VC, Nextech Invest, The Column Group, Third Rock Ventures, TWO Sigma Ventures, Agent Capital, Boxer Capital, Casdin Capital, ELI Lilly And Company, Invus Financial Advisors, Memorial Sloan Kettering Cancer Center, Nextech Invest, Novartis, Pavilion Capital, Aaron Davis, ShangBay Capital |
| Nov 1, 2022 | Casma Therapeutics | $46.0M Series C | — | Astellas Venture Management, The Column Group, Third Rock Ventures, Amgen Ventures, Eisai, Euclidean Capital, Mirae Asset, Tomotaka Okino, Schroders Capital |
| Jan 1, 2022 | Metagenomi | $180.0M Series B | Farallon Capital Management, Santhosh Palani, Phd, CFA | 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Humboldt Fund, Nextech Invest, OrbiMed, Tencent Holdings, Jeremy YAP, Bristol Myers Squibb, Deep Track Capital, Frazier Life Sciences, Irving Investors, Leaps BY Bayer, Marshall Wace, Millennium Management, Moderna, Novo Holdings, Pura Vida Investments, RA Capital Management, Surveyor Capital |
| Dec 1, 2021 | Freenome | $300.0M Series D | Ellen Hukkelhoven, Peter Kolchinsky | Anzu Partners, Ameena EL Bibany, Vasudev Bailey, ARTIS Ventures, Asset Management Ventures, Bain Capital Life Sciences, Cofounders Capital, Merck Global Health Innovation Fund, Polaris Partners, Section 32, Anne Wojcicki, Timothy A. Springer, Andreessen Horowitz, ArrowMark Partners, Brightedge Ventures, Byers Capital, Catalio Capital, Data Collective, Farallon Capital Management, Fidelity Management & Research Company, GV, HBM Healthcare Investments, Intermountain Ventures, Janus Henderson Investors, Kaiser Permanente, Logos Capital, Novartis, Polaris Partners, Pura Vida Investments, Ridgeback Capital Investments, Thomas Schinecker, Rock Springs Capital, Sands Capital, Soleus Capital, Suvretta Capital Management, T. Rowe Price Associates |
| Aug 1, 2021 | Dice Therapeutics | $60.0M Series C | RA Capital Management, Sands Capital | Samsara BioCapital, Versant Ventures, Asymmetry Capital Management, Deep Track Capital, Driehaus Capital Management, Janus Henderson Investors, Logos Capital, NEW Leaf Venture Partners, Northpond Ventures, Osage University Partners, Soleus Capital |
| Jul 1, 2021 | Turnstone Biologics | $80.0M Series D | Santhosh Palani, Phd, CFA, Point72 | KohFounders, Sofinnova Investments, VenBio Partners, Venrock, Versant Ventures, 404 BIO, Brace Pharma Capital, Caas Capital Management, F Prime Capital, JM Family Enterprises, Northleaf Capital Partners, OrbiMed, Ridgeback Capital Investments, Sectoral Asset Management, Sixty Degree Capital, Surveyor Capital, Takeda Ventures, Teralys Capital |
| Jun 1, 2021 | Kojin Therapeutics | $60.0M Series A | Luba Greenwood, Thomas Cahill, Amir Nashat | Flagship Ventures, NanoDimension, OrbiMed, Polaris Partners, Timothy A. Springer, TOM Hudson, Alexandria Venture Investments, Binney Street Capital, Juergen Eckhardt |
| May 1, 2021 | Flare Therapeutics | $82.0M Series A | Third Rock Ventures | Boxer Capital, Casdin Capital, Invus Financial Advisors, Nextech Invest |
| Jan 1, 2021 | Dice Therapeutics | $80.0M Series C | Jake Simson | Samsara BioCapital, Versant Ventures, Agent Capital, Alexandria Venture Investments, Altitude Life Science Ventures, Asymmetry Capital Management, Driehaus Capital Management, NEW Leaf Venture Partners, Northpond Ventures, Osage University Partners, Sands Capital, Sanofi Ventures, Soleus Capital |
| Dec 17, 2020 | Cullinan Therapeutics | $131.2M Series C | Foresite Capital | Baupost Group, Boxer Capital, BVF Partners, Cowen Healthcare Investments, F2 Ventures, Leerink Partners, Logos Capital, MPM Capital, Nextech Invest, OrbiMed, Rock Springs Capital, Schooner Capital, Venrock |
| Oct 6, 2020 | Talaris Therapeutics | $115.0M Series B | Surveyor Capital, Viking Global Investors | Aisling Capital, BlackRock, Blackstone, Cormorant Asset Management, Invus, Logos Capital, Longitude Capital, Pamoja Capital, Qiming Venture Partners USA |
| Jul 5, 2020 | Freeline | $120.0M Series C Extension | Eventide Asset Management, Thomas Dyrberg, Wellington Management | Acorn Bioventures, Ample Plus Fund, Cowen Healthcare Investments |
| Jul 2, 2020 | Annexon Biosciences | $100.0M Other Equity | Redmile Group | Adage Capital Management, Bain Capital Life Sciences, BlackRock, Blackstone, Deerfield Management, Farallon Capital Management, Janus Henderson Investors, Logos Capital, NEW Enterprise Associates, Satter Medical Technology Partners, Surveyor Capital |
| May 4, 2020 | Praxis Precision Medicines | $100.0M Other Equity | Kiran Reddy | Novo Holdings, Vida Ventures |
| Mar 1, 2020 | Pliant Therapeutics | $100.0M Series C | Novartis | Menlo Ventures, Agent Capital, Cormorant Asset Management, Cowen Healthcare Investments, Farallon Capital Management, Logos Capital, Anthology Fund, Redmile Group, Schroder Adveq, S Cubed Capital, Surveyor Capital |
| Dec 9, 2019 | Zentalis Pharmaceuticals | $85.0M Series C | — | Farallon Capital Management, Karan Takhar, Perceptive Advisors, Redmile Group, Surveyor Capital, Viking Global Investors |
| Apr 25, 2019 | Satsuma Pharmaceuticals | $62.0M Series B | Wellington Management | CAM Capital, Cormorant Asset Management, Lumira Ventures, Osage University Partners, RA Capital Management, SBI Investment, Snbl, Surveyor Capital, TPG Biotech |
| Apr 1, 2019 | KARUNA | $12.0M Series B Extension | — | Alexandria Venture Investments, ARCH Venture Partners, Fidelity Management & Research Company, Partner Fund Management, Pivotal BioVenture Partners, PureTech Health, Sands Capital, James Healy |
| Apr 1, 2019 | Karuna Therapeutics | $12.0M Series B Extension | — | Alexandria Venture Investments, Robert Nelsen, Fidelity Management & Research Company, Partner Fund Management, Heather Preston, PureTech Health, Sands Capital, James Healy |
| Feb 1, 2019 | Peloton Therapeutics | $150.0M Series E | Derek Dirocco | 305 Ventures, Foresite Capital, The Column Group, Gregory Bailey, BVF Partners, Curative Ventures, Driehaus Capital Management, EcoR1 Capital, Nextech Invest, OrbiMed, Tichenor Ventures, Topspin Fund, Vida Ventures |
| Jul 1, 2018 | Pliant Therapeutics | $62.0M Series B | Kevin Raidy | Menlo Ventures, Agent Capital, Anthology Fund, Schroder Adveq, S Cubed Capital |
